Cardiome Expects Anti-Arrhythmic NDA Submission By 2006
This article was originally published in Pharmaceutical Approvals Monthly
Cardiome plans NDA for lead anti-arrhythmic compound RSD1235 by 2006. In a Phase III study, 52% of patients with recent-onset atrial fibrillation converted to normal heart rhythm compared to 4% for placebo. RSD1235 could merit premium pricing to amiodarone (Wyeth’s Cordarone), Cardiome says
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class